73 related articles for article (PubMed ID: 23267890)
1. [Myeloid-derived suppressor cells in cancer patients].
Gonda K; Shibata M; Nakamura I; Kenjo A; Ohtake T; Yasuda M; Suzuki S; Suzuki H; Watanabe T; Fujimori K; Gotoh M; Takenoshita S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1797-9. PubMed ID: 23267890
[TBL] [Abstract][Full Text] [Related]
2. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer.
Ohki S; Shibata M; Gonda K; Machida T; Shimura T; Nakamura I; Ohtake T; Koyama Y; Suzuki S; Ohto H; Takenoshita S
Oncol Rep; 2012 Aug; 28(2):453-8. PubMed ID: 22614133
[TBL] [Abstract][Full Text] [Related]
3. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
4. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins.
Wang L; Chang EW; Wong SC; Ong SM; Chong DQ; Ling KL
J Immunol; 2013 Jan; 190(2):794-804. PubMed ID: 23248262
[TBL] [Abstract][Full Text] [Related]
5. [Myeloid-derived suppressor cells in patients with breast cancer].
Gonda K; Shibata M; Ohtake T; Yasuda M; Abe N; Watanabe K; Ando J; Okano M; Onozawa H; Tachibana K; Ohto H; Takenoshita S
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1363-8. PubMed ID: 22996770
[TBL] [Abstract][Full Text] [Related]
6. [Changes in myeloid-derived suppressor cells in malignant effusions of cancer patients following cancer chemotherapy].
Gonda K; Shibata M; Shimura T; Abe N; Suzuki S; Yasuda M; Nakamura I; Ohtake T; Ohki S; Watanabe T; Fujimori K; Suzuki S; Ohto H; Takenoshita S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2088-91. PubMed ID: 23267986
[TBL] [Abstract][Full Text] [Related]
7. Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells.
Younos I; Donkor M; Hoke T; Dafferner A; Samson H; Westphal S; Talmadge J
Int Immunopharmacol; 2011 Jul; 11(7):816-26. PubMed ID: 21376153
[TBL] [Abstract][Full Text] [Related]
8. [The number of myeloid-derived suppressor cells in the peripheral blood and tumor tissues in patients with gastric cancer and its clinical significance].
Xia R; Wang F; Gao T; Wen W; Lu B; Zhu Y; Zhang X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):740-3. PubMed ID: 25001941
[TBL] [Abstract][Full Text] [Related]
9. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.
Xu XD; Hu J; Wang M; Peng F; Tian R; Guo XJ; Xie Y; Qin RY
Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):99-105. PubMed ID: 26818550
[TBL] [Abstract][Full Text] [Related]
10. [Identification and significance of myeloid-derived suppressor cells in peripheral blood of breast cancer patients].
Wang CQ; Wei G; Xu GY; Wang JM; Bian J; Ma MS; Wang W; Xu D; Zhou ZJ; Zhao DD; Li H
Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):118-23. PubMed ID: 26899331
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
[TBL] [Abstract][Full Text] [Related]
12. Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease.
Rieber N; Brand A; Hector A; Graepler-Mainka U; Ost M; Schäfer I; Wecker I; Neri D; Wirth A; Mays L; Zundel S; Fuchs J; Handgretinger R; Stern M; Hogardt M; Döring G; Riethmüller J; Kormann M; Hartl D
J Immunol; 2013 Feb; 190(3):1276-84. PubMed ID: 23277486
[TBL] [Abstract][Full Text] [Related]
13. The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients.
Wang S; Fu Y; Ma K; Liu C; Jiao X; Du W; Zhang H; Wu X
Clin Transl Oncol; 2014 Jul; 16(7):616-22. PubMed ID: 24193866
[TBL] [Abstract][Full Text] [Related]
14. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.
Gabitass RF; Annels NE; Stocken DD; Pandha HA; Middleton GW
Cancer Immunol Immunother; 2011 Oct; 60(10):1419-30. PubMed ID: 21644036
[TBL] [Abstract][Full Text] [Related]
15. Amino acid metabolism related to immune tolerance by MDSCs.
Yang B; Wang X; Ren X
Int Rev Immunol; 2012 Jun; 31(3):177-83. PubMed ID: 22587019
[TBL] [Abstract][Full Text] [Related]
16. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.
Ye XZ; Yu SC; Bian XW
J Genet Genomics; 2010 Jul; 37(7):423-30. PubMed ID: 20659706
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.
Mougiakakos D; Jitschin R; von Bahr L; Poschke I; Gary R; Sundberg B; Gerbitz A; Ljungman P; Le Blanc K
Leukemia; 2013 Feb; 27(2):377-88. PubMed ID: 22828446
[TBL] [Abstract][Full Text] [Related]
18. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
Solito S; Bronte V; Mandruzzato S
J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
[TBL] [Abstract][Full Text] [Related]
19. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.
Haile LA; Gamrekelashvili J; Manns MP; Korangy F; Greten TF
J Immunol; 2010 Jul; 185(1):203-10. PubMed ID: 20525890
[TBL] [Abstract][Full Text] [Related]
20. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
Fujimura T; Mahnke K; Enk AH
J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
